| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/08/2011 | US7902159 Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
| 03/08/2011 | US7902158 Polysulfated glycosides and salts thereof |
| 03/08/2011 | US7902157 Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
| 03/08/2011 | US7902151 Methods and compositions for modulating immunity |
| 03/08/2011 | US7902148 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent |
| 03/08/2011 | US7902144 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 03/08/2011 | US7901917 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 03/08/2011 | US7901894 Kinase inhibitors |
| 03/08/2011 | US7901879 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 03/08/2011 | US7901716 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | US7901709 Active agent, a gel-phase lipid bilayer membrane of a phospholipid and a surface active agent contained in the bilayer membrane; increasing the percentage of active agent released at the phase transition temperature of the lipid bilayer |
| 03/08/2011 | US7901708 Liposomal apparatus and manufacturing methods |
| 03/08/2011 | US7901707 Biodegradable biocompatible implant and method of manufacturing same |
| 03/08/2011 | US7901698 Pharmaceutical compositions comprising silicones and two solubilized active principles |
| 03/08/2011 | US7901683 Methods of inhibiting amyloid toxicity |
| 03/08/2011 | US7901682 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation |
| 03/08/2011 | US7901674 Aldehyde-fixed platelets with internalized paramagnetic or magnetic nanoparticles |
| 03/08/2011 | US7901672 Methods of making enhanced, autologous fat grafts |
| 03/08/2011 | US7901650 Porous beta-tricalcium phosphate and methods for producing the same |
| 03/08/2011 | US7901432 Method for lateral implantation of spinous process spacer |
| 03/08/2011 | US7901383 Systems and methods for administering a medical regimen |
| 03/08/2011 | CA2689051C Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 03/08/2011 | CA2634381C Carbonylamino pyrrolopyrazoles, potent kinase inhibitors |
| 03/08/2011 | CA2571644C New association of a sinus node if current inhibitor and a converting enzyme inhibitor, and the pharmaceutical compositions containing them |
| 03/08/2011 | CA2557791C Controlled-release pharmaceutical composition and method for producing the same |
| 03/08/2011 | CA2529162C Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same |
| 03/08/2011 | CA2510181C Administration of capsaicinoids |
| 03/08/2011 | CA2498565C Composition for treating virus infection disease comprising jab1 |
| 03/08/2011 | CA2494812C Salt of morphine-6-glucuronide |
| 03/08/2011 | CA2488202C 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders |
| 03/08/2011 | CA2487532C Pyrrolidine derivatives as oxytocin antagonists |
| 03/08/2011 | CA2486915C Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | CA2468691C 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists |
| 03/08/2011 | CA2464721C Nitrogenous (tetrahydropyridyl) (alkyl) heterocycles with tnf activity |
| 03/08/2011 | CA2463987C Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
| 03/08/2011 | CA2460313C Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels |
| 03/08/2011 | CA2449217C Process for cleaning hard gelatine capsules |
| 03/08/2011 | CA2446756C Thiazole compounds useful as inhibitors of protein kinase |
| 03/08/2011 | CA2446748C Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods |
| 03/08/2011 | CA2440355C Fibrate-statin combinations with reduced fed-fasted effects |
| 03/08/2011 | CA2434272C Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 03/08/2011 | CA2432126C Complex of modafinil and cyclodextrin |
| 03/08/2011 | CA2426247C Particle formation methods and their products |
| 03/08/2011 | CA2423336C Stabilised fibrate microparticles |
| 03/08/2011 | CA2422531C Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 03/08/2011 | CA2420899C Hydroxamate derivatives useful as deacetylase inhibitors |
| 03/08/2011 | CA2415396C 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 03/08/2011 | CA2361251C Formulations comprising antisense nucleotides to connexins |
| 03/08/2011 | CA2357881C Polyfluoro copolymer coatings for implantable medical devices |
| 03/08/2011 | CA2338504C Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| 03/08/2011 | CA2329054C A novel polypeptide hormone phosphatonin |
| 03/08/2011 | CA2311734C Flash-melt oral dosage formulation |
| 03/08/2011 | CA2240516C Novel tyrosine kinase receptors and ligands |
| 03/03/2011 | WO2011026153A2 Inotilone derivatives as coherent biological response modifier (cbmr) |
| 03/03/2011 | WO2011026125A2 Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
| 03/03/2011 | WO2011026112A1 Compositions comprising specific ugt inhibitors and methods of use thereof |
| 03/03/2011 | WO2011026107A1 Phthalanilate compounds and methods of use |
| 03/03/2011 | WO2011026091A1 Imidazopyridazine compounds for treating viral infections |
| 03/03/2011 | WO2011026080A1 Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain |
| 03/03/2011 | WO2011026076A2 Topical formulations comprising a steroid |
| 03/03/2011 | WO2011026060A2 Treatment and prevention of secondary injury after trauma or damage to the central nervous system |
| 03/03/2011 | WO2011026041A2 Sdf-1 delivery for treating ischemic tissue |
| 03/03/2011 | WO2011026024A2 Imidazo [4,5-d] pyridazine compounds for treating viral infections |
| 03/03/2011 | WO2011026003A2 A xylitol containing comestible product |
| 03/03/2011 | WO2011025969A1 Compounds that treat malaria and prevent malaria transmission |
| 03/03/2011 | WO2011025968A1 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
| 03/03/2011 | WO2011025965A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025951A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025947A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025940A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025938A2 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025932A2 Preparation of sitagliptin and salts thereof |
| 03/03/2011 | WO2011025927A1 Compounds and compositions as protein kinase inhibitors |
| 03/03/2011 | WO2011025906A1 Long term potentiation with cyclic-glur6 analogs |
| 03/03/2011 | WO2011025889A1 HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS |
| 03/03/2011 | WO2011025862A2 Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1 |
| 03/03/2011 | WO2011025859A1 Condensed quinolines as protein kinase modulators |
| 03/03/2011 | WO2011025851A1 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| 03/03/2011 | WO2011025838A1 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| 03/03/2011 | WO2011025785A1 Methods for the prevention and treatment of cerebral ischemia |
| 03/03/2011 | WO2011025771A1 Compositions for delivery of insoluble agents |
| 03/03/2011 | WO2011025748A1 Amino substituted diaryl [a, d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 03/03/2011 | WO2011025706A2 Heterocyclic amide compounds as protein kinase inhibitors |
| 03/03/2011 | WO2011025690A1 Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| 03/03/2011 | WO2011025683A1 Hiv integrase inhibitors |
| 03/03/2011 | WO2011025566A1 Development of universal cancer drugs and vaccines |
| 03/03/2011 | WO2011025565A1 Morpholinone compounds as factor ixa inhibitors |
| 03/03/2011 | WO2011025556A1 Targeting pax2 for the treatment of breast cancer |
| 03/03/2011 | WO2011025545A1 Sphingosine type 1 inhibitors and methods for making and using same |
| 03/03/2011 | WO2011025541A1 Cannabinoid receptor modulators |
| 03/03/2011 | WO2011025540A1 Chemical induction of lactation |
| 03/03/2011 | WO2011025467A1 Solid dosage forms comprising telmisartan |
| 03/03/2011 | WO2011025270A2 Metformin caffeic acid salt, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same |
| 03/03/2011 | WO2011025269A2 Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same |
| 03/03/2011 | WO2011025267A2 Metformin methanesulfonate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same |
| 03/03/2011 | WO2011025230A2 Gaba release-regulating agent in cerebellum |
| 03/03/2011 | WO2011025220A2 Liver regeneration accelerator comprising betaine |
| 03/03/2011 | WO2011025167A2 Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof |
| 03/03/2011 | WO2011025128A2 Method for treating th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor |
| 03/03/2011 | WO2011025107A1 Composition for relieving pruritus |